Hide Assignment Information |
||||||||||
Turnitin™ |
||||||||||
This assignment will be submitted to Turnitin™. |
||||||||||
Instructions |
||||||||||
CTA Prototype Assignment Weight: 20% of Final Grade As discussed in class, in order for a clinical trial to be conducted in Canada, a Clinical Trial Application must be filed and approved by Health Canada before it can begin. As a regulatory affairs associate working for a large multinational pharmaceutical company, you have been asked to prepare a CTA for a new oncology product named “Sheridanumab”. The proposed study is for “An Open-label, Multicenter, Single-arm, Phase II Study of Sheridanumab in Patients with Germline BRCA1/2 Mutation and Platinum-sensitive Recurrent Ovarian Cancer”. You have previously held a pre-CTA meeting with Health Canada and have been given the green light to proceed with a CTA. 1. Create a prototype of your CTA, listing all relevant documents that you would need to file and what CTD section it would go in. If a CTA section does not apply, please indicate N/A. Please organize your Modules using the following tabular format:
2. Indicate what guidance document(s) you used to determine how to build your CTA prototype. 3. Summarize the differences between a CTA and IND.
General Instructions: |
||||||||||
4/2/24, 9:47 PM Case – HRM402 Training and Development (2024MAR04FT-1) 1/3 Module 3 – Case LEARNING STYLES; DEVELOPMENT OF TRAINING Assignment
4/2/24, 9:47 PM Case – HRM402 Training and Development (2024MAR04FT-1) 1/3 Module 3 – Case LEARNING STYLES; DEVELOPMENT OF TRAINING Assignment Overview Signature Assignment: Body of Knowledge, Introduced level In this assignment, your knowledge skills will be assessed at the “introduced” level. In MGT411, they will be assessed at the